Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the
mainstay of therapy for cardiovascular disease and heart failure (HF). The angiotensin …

Objective: Heart failure (HF) is a growing public health problem with high morbidity and
mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Recognition that neurohormonal activation plays a central role in the pathogenesis of heart
failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs) …

Abstract Sacubritil∗ valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a
combination drug described as a new class of dual-acting angiotensin receptor–neprilysin …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

What is known and objective Angiotensin receptor‐neprilysin inhibitor (ARNi) therapy has
been shown to improve cardiovascular outcomes in the Prospective Comparison of ARNi …

Background Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as
an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The …

Introduction The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan
(SAC/VAL) has shown benefit in patients with symptomatic heart failure (HF), including those …

Abstract Purpose of Review Numerous evidence-based medical and device therapies
proven to reduce morbidity and mortality have advanced care for heart failure with reduced …